跳至主要内容
临床试验/NCT00534976
NCT00534976已完成4 期

A Double-Blind, Placebo-Controlled, Multicenter, Crossover Study to Evaluate the Effects of a Single Oral Dose of Montelukast, Compared With Placebo, on Exercise-Induced Bronchoconstriction (EIB) in Pediatric Patients Aged 4 to 14 Years

Organon and Co0 个研究点目标入组 364 人开始时间: 2008年2月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
364
主要终点
Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Postdose

研究概览

简要总结

This study will see if there is a change in breathing after exercising when the child receives study drug ( montelukast or placebo). Breathing will be measured by a spirometer before exercising and measured again several times after exercising.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
4 Years 至 14 Years(Child)
性别
All
接受健康志愿者

入选标准

  • The child is 4 years to 14 years of age
  • The child is a non smoker
  • The child has exercise-induced bronchoconstriction (EIB)

排除标准

  • The child has active or chronic breathing disease, other than asthma
  • The child has required insertion of a breathing tube for asthma
  • The child had major surgery within the last 4 weeks
  • The child is currently in the hospital
  • The child has or had an upper respiratory tract infection within the last 2 weeks
  • The child has been hospitalized or visited the emergency room or had a change in their medication for asthma within the last 4 weeks
  • The child has been in a research study in the last 4 weeks
  • The child has stomach, brain, heart, kidney or liver disease
  • The child drinks more that 4 caffeinated drinks a day

结局指标

主要结局

Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Postdose

时间窗: Pre-exercise baseline and 0-60 minutes after the exercise challenge performed 2 hours post-dose

Maximum Percent Fall in FEV1 was defined as the % change from pre-exercise baseline FEV1 to the lowest FEV1 within 60 mins (minutes) after exercise. Spirometry measurements were taken 5 mins prior to each exercise challenge and immediately, 5, 10, 15, 30, 45, \& 60 mins after each exercise challenge. The 2-hour exercise challenges occurred 2 hours after the witnessed dose of study medication. The calculation used to produce the results was \[100\*(1-(X/Y))\] where X= the lowest FEV1 within 60 mins after exercise \& Y= pre-exercise baseline FEV1. Smaller values mean greater response to therapy.

次要结局

  • Area Under the Curve for FEV1 Percent Fall From Pre-exercise Baseline to 60 Minutes Following Exercise Challenge (AUC0-60 Min) at 2 Hours Post-dose(Pre-exercise baseline to 60 minutes after the exercise challenge performed 2 hours post-dose)
  • Number of Participants Requiring Rescue Medication at 2 Hours Postdose(0-90 minutes after the exercise challenge at 2 hours postdose)
  • Number of Participants Requiring Rescue Medication at 24 Hours Postdose(0-90 minutes after the exercise challenge at 24 hours postdose)
  • Maximum Percent Fall in FEV1 After Exercise Challenge at 24 Hours Post-dose(Pre-exercise baseline and 0-60 minutes after the exercise challenge performed 24 hours post-dose)
  • Area Under the Curve for FEV1 Percent Fall From Pre-exercise Baseline to 60 Minutes Following Exercise Challenge (AUC0-60 Min) at 24 Hours Post-dose(Pre-exercise baseline to 60 minutes after the exercise challenge performed 24 hours post-dose)
  • Time to Recovery From Maximum Percent Fall in FEV1 at 2 Hours Post-dose(0-60 minutes and 0-90 minutes after the exercise challenge at 2 hours postdose)
  • Time to Recovery From Maximum Percent Fall in FEV1 at 24 Hours Post-dose(0-60 minutes and 0-90 minutes after the exercise challenge at 24 hours postdose)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验